{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T11:08:12Z","timestamp":1648638492298},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"11-12","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1007\/s00508-012-0185-2","type":"journal-article","created":{"date-parts":[[2012,6,27]],"date-time":"2012-06-27T12:32:00Z","timestamp":1340800320000},"page":"412-418","source":"Crossref","is-referenced-by-count":1,"title":["Austrian Arbeitsgemeinschaft f\u00fcr Gyn\u00e4kologische Onkologie (AGO) guideline for prophylaxis with granulocyte colony-stimulating factors (G-CSF) in gynecologic malignancies, including breast cancer"],"prefix":"10.1007","volume":"124","author":[{"given":"Edgar","family":"Petru","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain Gustave","family":"Zeimet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Sevelda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Seifert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Hubalek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lukas","family":"Angleitner-Boubenizek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Speiser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Benedicic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Stummvoll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Reinthaller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,6,28]]},"reference":[{"key":"185_CR1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","volume":"47","author":"MS Aapro","year":"2011","unstructured":"Aapro MS, Bohlius J, Cameron D, et al. 2010 update of EORTC guidelines for the use of granulocyte colony stimulating factors to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011;47:8\u201332.","journal-title":"Eur J Cancer."},{"key":"185_CR2","doi-asserted-by":"crossref","first-page":"914","DOI":"10.6004\/jnccn.2011.0075","volume":"9","author":"J Crawford","year":"2011","unstructured":"Crawford J, Allen J, Armitage J, et al. For the National comprehensive cancer network. Myeloid growth factors. J Natl Compr Cancer Network. 2011;9:914\u201329.","journal-title":"J Natl Compr Cancer Network."},{"key":"185_CR3","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1200\/JCO.2006.06.4451","volume":"24","author":"TJ Smith","year":"2006","unstructured":"Smith TJ, Khatcheressian J, Lyman G, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24:3187\u2013205.","journal-title":"J Clin Oncol."},{"key":"185_CR4","doi-asserted-by":"crossref","first-page":"5555","DOI":"10.1002\/cncr.25332","volume":"116","author":"G Lyman","year":"2010","unstructured":"Lyman G, Kuderer, N, Crawford J, et al. Risk of mortality in patients with cancer who experience febrile neutropenia. Cancer. 2010;116:5555\u201363.","journal-title":"Cancer."},{"key":"185_CR5","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1200\/JCO.2005.05.645","volume":"23","author":"O Clark","year":"2005","unstructured":"Clark O, Lyman G, Castro A, Clark L, Djulbegovic I. Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol. 2005;23:4198\u2013212.","journal-title":"J Clin Oncol."},{"key":"185_CR6","unstructured":"Gohil S, Sharma A, Harper-Wynne C. Comparison of rates of febrile neutropenia using FEC100\/docetaxel100 chemotherapy in breast cancer patients with and without primary GCSF prophylaxis. National cancer research institute conference, 4\u20137 October, Birmingham, UK, 2009 (Abstract B75)."},{"key":"185_CR7","unstructured":"Head J, Archer C, Harper-Wynne C, et al. Rates of neutropenic sepsis with the use of adjuvant FEC100-docetaxel (FEC100-T) chemotherapy in high-risk node-positive patients with early breast cancer; a UK perspective. In: National cancer research institute conference, 5\u20138 October, Birmingham, UK, 2008 (Abstract B64)."},{"key":"185_CR8","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1093\/annonc\/mdf222","volume":"13","author":"EA Perez","year":"2002","unstructured":"Perez EA, Geeraerts L, Suman VJ, et al. A randomized phase II study of sequential docetaxel and doxorubicin\/cyclophosphamide in patients with metastatic breast cancer. Ann Oncol. 2002;13:1225\u201335.","journal-title":"Ann Oncol."},{"key":"185_CR9","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1200\/JCO.2005.05.078","volume":"23","author":"G Von Minckwitz","year":"2005","unstructured":"Von Minckwitz G, Raab G, Caputo A, et al. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German breast group. J Clin Oncol. 2005;23:2676\u201385.","journal-title":"J Clin Oncol."},{"key":"185_CR10","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1200\/JCO.2004.08.125","volume":"22","author":"E Alba","year":"2004","unstructured":"Alba E, Martin M, Ramos M, et al. Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line traetment of metastatic breast cancer: a spanish breast cancer research group (GEICAM-9903) phase III study. J Clin Oncol. 2004;22:2587\u201393.","journal-title":"J Clin Oncol."},{"key":"185_CR11","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1200\/JCO.2003.04.040","volume":"21","author":"JM Nabholtz","year":"2003","unstructured":"Nabholtz JM, Falkson C, Campos D, et al. Docetaxel and doxorubicin compared with doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol. 2003;21:968\u201375.","journal-title":"J Clin Oncol."},{"key":"185_CR12","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1200\/JCO.1995.13.11.2688","volume":"13","author":"L Gianni","year":"1995","unstructured":"Gianni L, Munzone E, Capri G, et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol. 1995;13:2688\u201399.","journal-title":"J Clin Oncol."},{"key":"185_CR13","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.1200\/JCO.2002.11.005","volume":"20","author":"L Biganzoli","year":"2002","unstructured":"Biganzoli L, Cufer T, Bruning P, et al. Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: the European organization for research and treatment of cancer 10961 multicenter phase III trial. J Clin Oncol. 2002;20:3114\u201321.","journal-title":"J Clin Oncol."},{"key":"185_CR14","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1093\/annonc\/mdm438","volume":"19","author":"G Von Minckwitz","year":"2008","unstructured":"Von Minckwitz G, Kummel S, DuBois A, et al. Pegfilgrastim +\/\u2212 ciprofloxacin for primary prophylaxis with TAC (docetaxel\/doxorubicin\/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study. Ann Oncol. 2008;19:292\u20138.","journal-title":"Ann Oncol."},{"key":"185_CR15","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1200\/JCO.2003.09.081","volume":"21","author":"ML Citron","year":"2003","unstructured":"Citron ML, Berry D, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741\/Cancer and Leukaemia Group B Trial 9741. J Clin Oncol. 2003;21:1431\u20139.","journal-title":"J Clin Oncol."},{"key":"185_CR16","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1016\/j.ejca.2006.05.002","volume":"42","author":"MS Aapro","year":"2006","unstructured":"Aapro MS, Cameron DA, Pettengell R, et al. EORTC guidelines for the use of granulocyte-colony stimulating factors to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer. 2006;42:2433\u201353.","journal-title":"Eur J Cancer."},{"key":"185_CR17","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1200\/JCO.2006.08.8823","volume":"25","author":"N Kuderer","year":"2007","unstructured":"Kuderer N, Dale D, Crawford J, Lyman G. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol. 2007;25:3158\u201367.","journal-title":"J Clin Oncol."},{"key":"185_CR18","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S0140-6736(09)61157-0","volume":"374","author":"N Katsumata","year":"2009","unstructured":"Katsumata N, Yasuda M, Takahashi F, et al. Dose-dense paclitaxel once a week in combination with careboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet. 2009;374:1331\u20138.","journal-title":"Lancet."},{"key":"185_CR19","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1200\/JCO.2000.18.14.2733","volume":"18","author":"C Verschraegen","year":"2000","unstructured":"Verschraegen C, Sittisomwong T, Kudelka A, et al. Docetaxel for patients with paclitaxel-resistant Mullerian carcinoma. J Clin Oncol. 2000;18:2733\u2013939.","journal-title":"J Clin Oncol."},{"key":"185_CR20","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1200\/JCO.2003.10.082","volume":"21","author":"GA Omura","year":"2003","unstructured":"Omura GA, Brady M, Look K, et al. Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose-levels in platinum-pretreated epithelial ovarian cancer: an intergroup study. J Clin Oncol. 2003;21:2843\u20138.","journal-title":"J Clin Oncol."},{"key":"185_CR21","doi-asserted-by":"crossref","unstructured":"Egawa-Takata T, Ueda Y, Kuragaki C, et al. Chemotherapy for endometrial carcinoma (GOGO-EM1 study): TEC (paclitaxel, epirubicin and carboplatin) is an effective remission induction and adjuvant therapy. Cancer Chemother Pharmacol. 2011, May 17. Epub ahead of print.","DOI":"10.1007\/s00280-011-1638-4"},{"key":"185_CR22","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.ygyno.2010.08.022","volume":"119","author":"D Cella","year":"2010","unstructured":"Cella D, Huang H, Homesley HD, et al. Patient-reported peripheral neuropathy of doxorubicin and cisplatin with and without paclitaxel in the treatment of advanced endometrial cancer: results from GOG 184. Gynecol Oncol. 2010;119:538\u201342.","journal-title":"Gynecol Oncol."},{"key":"185_CR23","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1200\/JCO.2002.11.050","volume":"20","author":"M Hensley","year":"2002","unstructured":"Hensley M, Maki R, Venkatraman E, et al. Gemcitabine and docetaxel in patients with unresesctable leiomyosarcoma: results of a phase II trial. J Clin Oncol. 2002;20:2824\u201331.","journal-title":"J Clin Oncol."},{"key":"185_CR24","unstructured":"Fachinformation Neupogen\u00ae Stand Februar 2011, Fachinformation Ratiograstim\u00ae Stand M\u00e4rz 2011, Fachinformation Zarzio\u00ae Stand M\u00e4rz 2011."},{"key":"185_CR25","unstructured":"Fachinformation Neulasta\u00ae Stand Mai 2011."},{"issue":"Suppl","key":"185_CR26","first-page":"15","volume":"27","author":"J Sierra","year":"2009","unstructured":"Sierra J, Harms R, Mo M, Vogel C. Evaluation of reported bone pain in patients receiving chemotherapy in pegfilgrastim clinical trials. J Clin Oncol. 2009;27(Suppl\u00a020):15 (Abstract 9621).","journal-title":"J Clin Oncol."},{"key":"185_CR27","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1200\/JCO.2000.18.13.2522","volume":"18","author":"E Johnston","year":"2000","unstructured":"Johnston E, Crawford J, Blackwell S, et al. Randomized, dose-escalation study of SD\/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol. 2000;18:2522\u20138.","journal-title":"J Clin Oncol."},{"key":"185_CR28","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1200\/JCO.2009.25.8723","volume":"28","author":"G Lyman","year":"2010","unstructured":"Lyman G, Dale D, Wolff D, Culakova E, et al. Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review. J Clin Oncol. 2010;28:2914\u201324.","journal-title":"J Clin Oncol."},{"key":"185_CR29","doi-asserted-by":"crossref","first-page":"6908","DOI":"10.1200\/JCO.2005.03.099","volume":"23","author":"P Papaldo","year":"2005","unstructured":"Papaldo P, Lopez M, Marolla P, et al. Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide. J Clin Oncol. 2005;23:6908\u201318.","journal-title":"J Clin Oncol."},{"key":"185_CR30","doi-asserted-by":"crossref","first-page":"3874","DOI":"10.1200\/JCO.1998.16.12.3874","volume":"16","author":"G Toner","year":"1998","unstructured":"Toner G, Shapiro J, Laidlow C, et al. Low-dose versus standard-dose lenograstim prophylaxis after chemotherapy: a randomized, crossover comparison. J Clin Oncol. 1998;16:3874\u20139.","journal-title":"J Clin Oncol."},{"key":"185_CR31","unstructured":"Bartelt M, Harman S, Lower E. Halved pegfilgrastim doses in adjuvant breast cancer patients associated with similar efficacy but reduced toxicity. Breast Cancer Res Treat. 2007;106(Suppl\u00a01):S105\u20136."},{"issue":"Suppl","key":"185_CR32","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S0093-7754(03)00312-9","volume":"30","author":"G Lyman","year":"2003","unstructured":"Lyman G. Balancing the benefits and costs of colony-stimulating factors: a current perspective. Semin Oncol. 2003;30(Suppl\u00a013):10\u20137.","journal-title":"Semin Oncol."},{"key":"185_CR33","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1200\/JCO.2005.04.3281","volume":"24","author":"J Timmer-Bonte","year":"2006","unstructured":"Timmer-Bonte J, Adang E, Smit H, et al. Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in small-cell lung cancer. J Clin Oncol. 2006;24:2991\u20137.","journal-title":"J Clin Oncol."}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-012-0185-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00508-012-0185-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-012-0185-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T21:53:29Z","timestamp":1559080409000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00508-012-0185-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":33,"journal-issue":{"issue":"11-12","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["185"],"URL":"https:\/\/doi.org\/10.1007\/s00508-012-0185-2","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6]]}}}